Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 12-Month Low After Analyst Downgrade

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s share price hit a new 52-week low during trading on Friday after Wells Fargo & Company lowered their price target on the stock from $1,050.00 to $900.00. Wells Fargo & Company currently has an overweight rating on the stock. Regeneron Pharmaceuticals traded as low as $691.00 and last traded at $698.34, with a volume of 492017 shares changing hands. The stock had previously closed at $733.59.

A number of other research analysts have also recently commented on the stock. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Canaccord Genuity Group assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. Sanford C. Bernstein decreased their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research note on Tuesday. Wolfe Research initiated coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price objective on the stock. Finally, Barclays decreased their target price on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,037.33.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. International Assets Investment Management LLC grew its position in shares of Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after acquiring an additional 879,916 shares during the period. Worldquant Millennium Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the third quarter valued at approximately $127,489,000. Icon Wealth Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 18,342.0% in the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock valued at $79,874,000 after buying an additional 75,569 shares in the last quarter. State Street Corp raised its stake in shares of Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after buying an additional 61,277 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its position in shares of Regeneron Pharmaceuticals by 12.4% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company’s stock valued at $567,864,000 after buying an additional 59,769 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 5.0 %

The stock has a market cap of $76.58 billion, a price-to-earnings ratio of 17.25, a PEG ratio of 2.19 and a beta of 0.10. The business’s 50 day moving average is $751.44 and its 200-day moving average is $962.58. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.